HC Wainwright & Co. Reiterates Neutral on Kyverna Therapeutics, Maintains $8 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated a Neutral rating on Kyverna Therapeutics (NASDAQ:KYTX) and maintained a price target of $8.
July 16, 2024 | 11:58 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
HC Wainwright & Co. has reiterated a Neutral rating on Kyverna Therapeutics and maintained a price target of $8.
The reiteration of a Neutral rating and maintenance of the $8 price target suggests that the analyst does not see significant short-term upside or downside potential for Kyverna Therapeutics. This is likely to result in a neutral impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100